Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research

Despite all scientific efforts and many protracted and expensive clinical trials, no new drug has been approved by FDA for treatment of Alzheimer disease (AD) since 2003. Indeed, more than 200 investigational programs have failed or have been abandoned in the last decade. The most probable explanati...

Descripción completa

Detalles Bibliográficos
Autores principales: Yiannopoulou, Konstantina G., Anastasiou, Aikaterini I., Zachariou, Venetia, Pelidou, Sygkliti-Henrietta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966425/
https://www.ncbi.nlm.nih.gov/pubmed/31835422
http://dx.doi.org/10.3390/biomedicines7040097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966425/
https://www.ncbi.nlm.nih.gov/pubmed/31835422
http://dx.doi.org/10.3390/biomedicines7040097

Ejemplares similares